Somapacitan
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Somapacitan |
| DrugBank ID | DB15093 |
| Brand Names (EU) | Sogroya |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 95.73% |
Approved Indication (EMA)
Sogroya is indicated for the replacement of endogenous growth hormone (GH) in children aged 3 years and above, and adolescents with growth failure due to growth hormone deficiency (paediatric GHD), and in adults with growth hormone deficiency (adult GHD).
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | allergic asthma | 95.73% | DL |
| 2 | intrinsic asthma | 95.34% | DL |
| 3 | brain small vessel disease 1 with or without ocular anomalies | 92.08% | DL |
| 4 | autosomal dominant familial hematuria-retinal arteriolar tortuosity-contractures syndrome | 92.06% | DL |
| 5 | renin-angiotensin-aldosterone system-blocker-induced angioedema | 91.84% | DL |
| 6 | gout | 91.60% | DL |
| 7 | autoimmune hemolytic anemia | 91.21% | DL |
| 8 | diabetic nephropathy | 90.98% | DL |
| 9 | asthma-related traits, susceptibility to | 89.65% | DL |
| 10 | disorder of GPI anchor biosynthesis | 89.30% | DL |
| 11 | acquired aplastic anemia | 88.82% | DL |
| 12 | bronchitis | 88.49% | DL |
| 13 | exostosis | 87.66% | DL |
| 14 | hemoglobinuria | 87.57% | DL |
| 15 | asthma | 86.32% | DL |
| 16 | tendinitis | 85.69% | DL |
| 17 | migraine with brainstem aura | 85.29% | DL |
| 18 | idiopathic granulomatous myositis | 84.76% | DL |
| 19 | myositis fibrosa | 84.76% | DL |
| 20 | migraine disorder | 84.30% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.